Literature DB >> 7427030

Possible test for selection of adjuvant systemic therapy in early cancer of the breast.

T Cooke, W D George, K Griffiths.   

Abstract

The estrogen receptor content and the thymidine labelling index have been correlated in a series of primary cancers of the breast. Receptor was assayed in tumours of 409 patients with operable breast cancer. Recurrence rates were significantly higher in patients whose tumours did not contain receptors than in those whose tumours did. Women without axillary node involvement whose tumours lacked oestrogen receptors showed the same high rate of recurrence as all women with axillary involvement. The oestrogen receptor status of metatases was similar to that of the primary tumours. The thymidine labelling of 83 tumours was inversely related to their receptor content. Tumours without receptors had the highest indices and therefore the highest potential tumour growth. These results have been discussed in relation to selection of systemic adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7427030     DOI: 10.1002/bjs.1800671018

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  4 in total

1.  Oestrogen receptors and survival in early breast cancer.

Authors:  T Cooke
Journal:  Br Med J (Clin Res Ed)       Date:  1982-04-10

2.  Adjuvant chemotherapy of breast cancer: hope--reality--hazard?

Authors:  H Vorherr
Journal:  Klin Wochenschr       Date:  1984-02-15

3.  The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.

Authors:  J M Howat; M Harris; R Swindell; D M Barnes
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

4.  The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease.

Authors:  J M Howat; D M Barnes; M Harris; R Swindell
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.